- Home
- TOPS vs MBRX Comparison
TOPS vs MBRX Comparison
Compare TOPS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOPS | MBRX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 13.2M |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TOPS | MBRX |
|---|---|---|
| Price | $0.90 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 1.1M | 202.8K |
| Earning Date | 04-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.25 |
| 52 Week High | $11.47 | $7.98 |
Technical Indicators
Market Signals| Indicator | TOPS | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 18.26 | 67.22 |
| Support Level | N/A | $0.39 |
| Resistance Level | $6.18 | $5.22 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 1.36 | 87.22 |
Price Performance
Historical ComparisonAbout TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.